TORONTO, Jan. 24, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced today that
the company has been selected to present an oral platform entitled
"AMF-1c-120: an antibody specific for misfolded prion protein expressed on
ovarian cancer cells", at the annual meeting of the American Association for
Cancer Research (AACR) in Washington, DC on April 9, 2013.
The Company will present the results of studies demonstrating the selective
binding of its proprietary antibody, AMF-1c-120, to ovarian cancer cells, but
not normal ovarian cells, as well as the killing of ovarian cancer cells with
an antibody-toxin conjugate. These results validate the Company's ProMIS™
discovery technology as a valuable scientific platform enabling the
development of novel, targeted therapeutic antibodies for the treatment of
cancer and other diseases.
Dr. Neil Cashman, Amorfix's Chief Scientific Officer said, "It is an honour to
be one of the few participants selected for an oral presentation at this
premier cancer research conference. We look forward to sharing our exciting
results with the scientific community working to battle this common and
The Company is developing AMF-1c-120 as a new therapeutic for the treatment of
ovarian cancer and is in preclinical animal models of disease at present.
The Company is also developing additional antibodies for the treatment of
other types of cancers with their unique and proprietary ProMIS™ platform
for identifying cancer specific targets that spare normal cells.
About the ProMIS Discovery Technology and the Company's Prion Protein (PrP)
Amorfix's proprietary drug discovery technology, ProMIS™, is a computer
based algorithm that predicts Disease Specific Epitopes (DSEs), those regions
of proteins most likely to misfold in diseases. Misfolded proteins are found
in numerous diseased cells, including various cancers and neurodegenerative
diseases. The Company uses this technology to identify DSEs which are only
expressed on tumor cells and not on normal cells as a way of developing
antibodies that only bind to and kill tumor cells without affecting normal
cells. Using this technology, Amorfix has the potential to create antibody
therapeutics that are more efficacious and have a much better safety profile,
with fewer side effects than current cancer therapeutics.
About Ovarian Cancer
Ovarian cancer is the fifth most common cancer among women, and it causes more
deaths than any other type of female reproductive cancer. Most deaths from
ovarian cancer occur in women age 55 and older. Ovarian cancer is often not
diagnosed until late-stage disease when the cancer has spread to other organs
in the body, which contributes to the short survival time following diagnosis.
Ovarian cancer is typically treated with surgery and chemotherapy.
Chemotherapy is not very effective as a treatment and is associated with a
number of potential dose-limiting side effects due to its non-specific killing
of both tumour and normal cells.
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development
company developing therapeutic antibodies and diagnostics targeting misfolded
protein diseases. Amorfix utilizes its computational discovery platform,
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this technology, Amorfix is developing
novel antibody therapeutics and companion diagnostics for cancer and
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two
proprietary technologies to specifically identify very low levels of misfolded
proteins in a biological sample: Epitope Protection™ and AMFIA™, an
ultra-sensitive dual-bead immunoassay. Use of these technologies has generated
a human cerebrospinal fluid (CSF) screening test for Alzheimer's disease (AD)
and mild cognitive impairment (MCI), and an ultrasensitive method for
detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF
and blood from animal models of AD. For more information about Amorfix, visit
The TSX has not reviewed and does not accept responsibility for the adequacy
or accuracy of this release. This information release may contain certain
forward-looking information. Such information involves known and unknown
risks, uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those implied by
statements herein, and therefore these statements should not be read as
guarantees of future performance or results. All forward-looking statements
are based on the Company's current beliefs as well as assumptions made by and
information currently available to it as well as other factors. Readers are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by the Company
in its public securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 email@example.com Janet
Clennett Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416)
847-6926 Fax: (416) 847-6899 firstname.lastname@example.org
SOURCE: Amorfix Life Sciences Ltd.
To view this news release in HTML formatting, please use the following URL:
CO: Amorfix Life Sciences Ltd.
NI: MTC SHOW
Press spacebar to pause and continue. Press esc to stop.